EE317 Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Gree A Cost Utility Analysis
Abstract
Authors
Katerina Vellopoulou Stylianos Ravanidis Aggeliki Giannakopoulou Nikolas Kourkoulas Alexandros Sfikas Nikolas Mathioudakis Georgia Kourlaba